Atypical diffuse bilateral cystic lung changes secondary to erlotinib treatment in a patient with metastatic non-small cell lung carcinoma: A case report and literature review

Erlotinib is a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor (EGFR) mutations. The response rate to erlotinib is ~...

全面介紹

Na minha lista:
書目詳細資料
發表在:Mol Clin Oncol
Main Authors: Ansari, Jawaher, Batubara, Enas, Ali, Muhammad, Farrag, Ashraf, Bashir, Farhat, Farghaly, Hussein R., Ali, Arwa M., Shaukat, Arif
格式: Artigo
語言:Inglês
出版: D.A. Spandidos 2018
主題:
Articles
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6030992/
https://ncbi.nlm.nih.gov/pubmed/29977544
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2018.1620
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍